Quarterly ResultMay 12, 2026, 04:18 PM
Stereotaxis Q1 Revenue $6.3M; Net Loss ($5.9M); Robocath Acquisition
AI Summary
Stereotaxis reported Q1 2026 revenue of $6.3 million, a decrease from $7.5 million in the prior year, resulting in a net loss of ($5.9) million. Despite the financial decline, the company achieved significant milestones including US FDA approvals for its MAGiC catheter and Synchrony digital operating room system, which are now being commercialized. Additionally, Stereotaxis announced a definitive agreement to acquire Robocath, aiming to create a leading robotic platform. The company projects double-digit revenue growth for the full year 2026, expecting to surpass $40 million.
Key Highlights
- Definitive agreement to acquire Robocath, combining complementary robotic technologies for endovascular procedures.
- Proprietary MAGiC catheter received US FDA approval in January and is now utilized at multiple sites.
- Synchrony digital operating room system received US FDA clearance in April, with initial orders and shipments.
- Q1 2026 total revenue was $6.3 million, down from $7.5 million in Q1 2025.
- Q1 2026 net loss was ($5.9) million, compared to ($5.8) million in Q1 2025.
- Q1 2026 gross margin was 60% of revenue; recurring revenue gross margin was 66%.
- Cash and cash equivalents were $14.6 million at March 31, 2026, with no debt.
- Anticipates full-year 2026 revenue to surpass $40 million with double-digit growth.
Price Impact
More from STXS